Targets › CLDN4
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2030.
Can associate with other claudins to regulate tight junction structural and functional strand dynamics. May coassemble with CLDN8 into tight junction strands containing anion-selective channels that convey paracellular chloride permeability in renal collecting ducts (By similarity). (UniProt, O14493)
Open in Phaseline: the race on CLDN4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Astellas | ASP1002 Anti-CLDN4 antibody-drug conjugate | CLDN4 | Phase 1 | Advanced Solid Tumors | Apr 2030 |
Advanced Solid Tumors (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.